Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits

Journal of the American Association for Laboratory Animal Science

Volumn 53, Issue 3, 2014, Pages 283-289

  Diaz, Leslie L ^a   Zhang, Jingwei ^b   Heerdt, Paul M ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISATRACURIUM; CW 002; CYSTEINE; GLYCOPYRRONIUM BROMIDE; ISOFLURANE; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROL; DOSE RESPONSE; DRUG POTENCY; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; MUSCLE TWITCH; MUSCLE WEAKNESS; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; NONHUMAN; RABBIT; STANDARD;

ANIMALS; ATRACURIUM; BLOOD PRESSURE; CROSS-OVER STUDIES; HEART RATE; ISOFLURANE; ISOQUINOLINES; MALE; NEUROMUSCULAR BLOCKING AGENTS; PANCURONIUM; RABBITS;

EID: 84900543303     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ali HH, Utting JE, Gray C. 1970. Stimulus frequency in the detection of neuromuscular block in humans. Br J Anaesth 42:967-978.
2. Ali HH, Utting JE, Gray TC. 1971. Quantitative assessment of residual antidepolarizing block. I. Br J Anaesth 43:473-477.
3. Ali HH, Utting JE, Gray TC. 1971. Quantitative assessment of residual antidepolarizing block. II. Br J Anaesth 43:478-485.
4. Baird WL, Reid AM. 1967. The neuromuscular blocking properties of a new steroid compound, pancuronium bromide. A pilot study in man. Br J Anaesth 39:775-780.
5. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ. 1995. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 82:1139-1145.
6. Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ. 2004. Clinical pharmacology of GW280430A in humans. Anesthesiology 100:768-773.
7. Bevan DR, Smith CE, Donati F. 1988. Postoperative neuromuscular blockade: a comparison between atracurium, vecuronium, and pancuronium. Anesthesiology 69:272-276.
8. Bluestein LS, Stinson LW Jr, Lennon RL, Quessy SN, Wilson RM. 1996. Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation. Can J Anaesth 43:925-931.
9. Bom A, Bradley M, Cameron K, Clark JK, van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang M-Q. 2002. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 41:266-270.
10. Brull SJ, Murphy GS. 2010. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg 111:129-140.
11. Cammu G, de Baerdemaeker L, den Blauwen N, de Mey JC, Struys M, Mortier E. 2002. Postoperative residual curarization with cisatracurium and rocuronium infusions. Eur J Anaesthesiol 19:129-134.
12. Flecknell PA. 1996. Special techniques. Laboratory animal anaesthesia: a practical introduction for research workers and technicians. San Diego (CA): Academic Press.
13. Fok TF, al-Essa M, Monkman S, Dolovich M, Girard L, Coates G, Kirpalani H. 1997. Delivery of metered-dose inhaler aerosols to paralyzed and nonparalyzed rabbits. Crit Care Med 25:140-144.
14. Heerdt PM, Kang R, The A, Hashim M, Mook RJ Jr, Savarese JJ. 2004. Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology 100:846-851.
15. Heerdt PM, Malhotra JK, Pan BY, Sunaga H, Savarese JJ. 2010. Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs. Anesthesiology 112:910-916.
16. Hindman BJ, Funatsu N, Cheng DC, Bolles R, Todd MM, Tinker JH. 1990. Differential effect of oncotic pressure on cerebral and extracerebral water content during cardiopulmonary bypass in rabbits. Anesthesiology 73:951-957.
17. Institute for Laboratory Animal Research. 2011. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): National Academies Press.
18. Ivey ES, Morrisey JK. 2000. Therapeutics for rabbits. Vet Clin North Am Exot Anim Pract 3:183-220 [vii.].
19. Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM, Bowling AC, Newman HC, Jenkins AL, Goff DV. 1981. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 34:362-366.
20. Jiang Y, Bhargava V, Lal HA, Mittal RK. 2011. Variability in the muscle composition of rat esophagus and neural pathway of lower esophageal sphincter relaxation. Am J Physiol Gastrointest Liver Physiol 301:G1014-G1019.
21. Kim KS, Shim JC, Jun JH, Lee KH, Chung CW. 1999. Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium. Anesth Analg 88:654-658.
22. Kopman AF, Zank LM, Ng J, Neuman GG. 2004. Antagonism of cisatracurium and rocuronium block at a tactile train-of-4 count-of-2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg 98:102-106.
23. Kraft SA, Larson CP Jr, Shuer LM, Steinberg GK, Benson GV, Pearl RG. 1990. Effect of hyperglycemia on neuronal changes in a rabbit model of focal cerebral ischemia. Stroke 21:447-450.
24. Lien CA. 2011. Development and potential clinical impairment of ultrashort-acting neuromuscular blocking agents. Br J Anaesth 107 Suppl 1:i60-i71.
25. Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ. 2009. Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J Crit Care 24:50-57.
26. Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ. 1996. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide-opioid-barbiturate anesthesia. Anesthesiology 84:300-308.
27. Lowry DW, Mirakhur RK, McCarthy GJ, Carroll MT, McCourt KC. 1998. Neuromuscular effects of rocuronium during sevoflurane, isoflurane, and intravenous anesthesia. Anesth Analg 87:936-940.
28. Miller RD, Roderick LL. 1978. Acid-base balance and neostigmine antagonism of pancuronium neuromuscular blockade. Br J Anaesth 50:317-324.
29. Mills P, Sessler DI, Moseley M, Chew W, Pereira B, James TL, Litt L. 1987. An in vivo 19 F nuclear magnetic resonance study of isoflurane elimination from the rabbit brain. Anesthesiology 67:169-173.
30. Muzzin S, Trippenbach T, Baconnier P, Benchetrit G. 1989. Entrainment of the respiratory rhythm by periodic lung inflation during vagal cooling. Respir Physiol 75:157-172.
31. Nielsen HK, May O. 1994. The optimal administration time for neostigmine following atracurium blockade. Kinetics of antagonists. Anaesthesist 43:528-533.
32. Savarese JJ, Lien CA, Belmont MR, Wastila WB. 1997. The clinical pharmacology of new benzylisoquinoline-diester compounds, with special consideration of cisatracurium and mivacurium. Anaesthesist 46:840-849.
33. Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savard PM, Heerdt PM. 2010. Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology 113:58-73.
34. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. 2003. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553-558.
35. Scheufler KM, Thees C, Nadstawek J, Zentner J. 2003. S(+)-ketamine attenuates myogenic motor-evoked potentials at or distal to the spinal α-motoneuron. Anesth Analg 96:238-244.
36. Shorten GD, Ali HH, Goudsouzian NG. 1993. Neostigmine and edrophonium antagonism of moderate neuromuscular block induced by pancuronium or tubocurarine. Br J Anaesth 70:160-162.
37. Sparr HJ, Beaufort TM, Fuchs-Buder T. 2001. Newer neuromuscular blocking agents: how do they compare with established agents? Drugs 61:919-942.
38. Sunaga H, Malhotra JK, Yoon E, Savarese JJ, Heerdt PM. 2010. Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology. Anesthesiology 112:900-909.
39. Terakawa Y, Ichinohe T, Kaneko Y. 2010. Rocuronium and vecuronium do not affect mandibular bone marrow and masseter muscular blood flow in rabbits. J Oral Maxillofac Surg 68:15-20.
40. Veres-Nyeki KO, Rieben R, Spadavecchia C, Bergadano A. 2012. Pancuronium dose refinement in experimental pigs used in cardiovascular research. Vet Anaesth Analg 39:529-532.
41. Wastila WB, Maehr RB, Turner GL, Hill DA, Phil M, Savarese JJ. 1996. Comparative pharmacology of cisatracurium (51W89), atracurium, and 5 isomers in cats. Anesthesiology 85:169-177.
42. Yoshida T, Uchiyama A, Matsuura N, Mashimo T, Fujino Y. 2013. The comparison of spontaneous breathing and muscle paralysis in 2 different severities of experimental lung injury. Crit Care Med 41:536-545.